<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1327">
  <stage>Registered</stage>
  <submitdate>31/05/2006</submitdate>
  <approvaldate>3/08/2006</approvaldate>
  <actrnumber>ACTRN12606000328572</actrnumber>
  <trial_identification>
    <studytitle>Use of heparin to prevent lung microvascular thrombosis in patients administered aprotinin undergoing cardiac surgery for ischemic heart disease</studytitle>
    <scientifictitle>Use of heparin to prevent lung microvascular thrombosis in patients administered aprotinin undergoing cardiac surgery for ischemic heart disease for ischemic heart disease</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Ischaemic heart disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Therapeutic heparin intravenous infusion (18U/kg/Hr) over the 3 hours prior to commencement of surgery.</interventions>
    <comparator>Control group will receive an equivalent infusion of 5% dextrose with no active drug.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Evidence of microvascular thrombosis on lung biopsy</outcome>
      <timepoint>Taken at the end of cardiac surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Alveolar dead space </outcome>
      <timepoint>Meausured at induction and at the end of cardiac surgery.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Elective cardiac surgery.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Repeat cardiac surgery , complex surgery.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>yes, contacting the holder of the allocation schedule who is "off-site"</concealment>
    <sequence>Randomisation table generated by computer software into blocks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>8/08/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St. Vincents Hospital Melbourne</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>St Vincents Health Melbourne intensive care unit</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>St. Vincents Hospital Melbourne</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients undergoing cardiac surgery administered aprotinin will be enrolled. Patients will be randomised to receive a pre-operative heaprin infusion or placebo. A lung biopsy will be taken to determine if pre-operative heaprin prevents the development of microvascular thrombosis in the lungs.

Hypothesis. Heparin prevents the formation of blood clots in the lungs following cardiac surgery.

The patients enrolled, the therapists and the data collectors will all be blinded.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincents Melbourne,</ethicname>
      <ethicaddress />
      <ethicapprovaldate>27/07/2006</ethicapprovaldate>
      <hrec>067/06</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Barry Dixon</name>
      <address>St. Vincents Hospital
Victoria Parade
Fitzroy VIC 3065</address>
      <phone>+61 3 92884488</phone>
      <fax>+61 3 92884487</fax>
      <email>barry.dixon@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Barry Dixon</name>
      <address>St. Vincents Hospital
Victoria Parade
Fitzroy VIC 3065</address>
      <phone>+61 3 92884488</phone>
      <fax>+61 3 92884487</fax>
      <email>barry.dixon@svhm.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>